EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Dextromethorphan-Bupropion-Esketamine Triadic Pharmacology: Molecular Targets, Enzymatic Interactions, and Risk-Benefit Assessment of a Three-Agent Combination for Treatment-Resistant Depression

Andrea Fagiolini iD, Alessandro Cuomo iD, Giulio Corrivetti, Mario Pinzi iD, Pietro Carmellini, Alessandra Marenna iD, Francesco Monaco iD, Annarita Vignapiano iD, Eva Frigola-Capell iD, The Opade Group

International Journal of Molecular Sciences · 09.11.2026 · 27 (21) · 10036

DOI: 10.3390/ijms272110036 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 09.11.2026. Verfasst von Andrea Fagiolini und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular and Developmental Medicine, University of Siena, Viale Bracci 16, 53100 Siena, Italy. Hauptthemen laut MEDLINE: Dextromethorphan, Bupropion, Ketamine, Depression. Die Arbeit nennt 76 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: European Union's Horizon Europe research and innovation programme, European Union’s Horizon Europe research and innovation programme.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Dextromethorphan is extensively O-demethylated by cytochrome P450 2D6 (CYP2D6) to dextrorphan, and the two molecules do not share a target profile. Dextrorphan is the more potent N-methyl-D-aspartate (NMDA) channel blocker; the parent compound is the more potent serotonin transporter inhibitor; their sigma-1 affinities are comparable, so differences in sigma-1 engagement depend on exposure rather than intrinsic affinity. CYP2D6 activity therefore does not scale exposure to a fixed pharmacology; it determines which pharmacology is expressed. This review develops that principle and extends it to a three-agent system. From published unbound concentrations and functional potencies, we calculate a model-derived fractional-target-engagement index. Under the base-case inputs, CYP2D6 inhibition raises the serotonergic index approximately fourfold while reducing the NMDA channel index; deterministic sensitivity analysis shows that the direction is robust to one-at-a-time 0.5-fold to 2-fold perturbations but not to all joint extreme assumptions. Quinidine and bupropion are analyzed as mechanistically distinct proofs of concept, and quinidine-derived exposure estimates are not treated as quantitative surrogates for the dextromethorphan–bupropion steady state. The framework is then applied to the untested question of whether a boosted dextromethorphan combination and esketamine are redundant or complementary. The agents share an NMDA channel mechanism, while CYP2B6 pathway overlap remains a hypothesis-generating observation rather than evidence of clinically relevant competition. No controlled data on the three-agent combination exist, and no therapeutic recommendation is made.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DextromethorphanBupropionKetamineDepressionHumansCytochrome P-450 CYP2D6Receptors, sigmaSigma-1 ReceptorRisk AssessmentCytochrome P-450 CYP2D6 Inhibitors

Stichwörter der Autor:innen

CYP2B6CYP2D6NMDA receptorbupropiondextromethorphandextrorphanesketaminepharmacogenomicspharmacokinetic boostingsigma-1 receptor

Substanzen

DextromethorphanBupropionCytochrome P-450 CYP2D6KetamineEsketamineReceptors, sigmaSigma-1 ReceptorCytochrome P-450 CYP2D6 Inhibitors

Autor:innen und Institutionen

  • Department of Molecular and Developmental Medicine, University of Siena, Viale Bracci 16, 53100 Siena, Italy.
  • European Biomedical Research Institute of Salerno, EBRIS, Via Salvatore De Renzi 50, 84125 Salerno, Italy.
  • Mental Health and Addictions Research Group, Institut d'Investigació Biomèdica de Girona (IDIBGI-CERCA), Departament de Salut, Generalitat de Catalunya, Parc Hospitalari Martí i Julià, Edifici M2, 17190 Salt, Spain.

ORCID-Profile: Andrea Fagiolini, Alessandro Cuomo, Mario Pinzi, Alessandra Marenna, Francesco Monaco, Annarita Vignapiano, Eva Frigola-Capell

Förderung

  • European Union's Horizon Europe research and innovation programme
  • European Union’s Horizon Europe research and innovation programme

Zitieren

APA

Fagiolini, A., Cuomo, A., Corrivetti, G., Pinzi, M., Carmellini, P., Marenna, A., Monaco, F., Vignapiano, A., Frigola-Capell, E., & The Opade Group (2026). Dextromethorphan-Bupropion-Esketamine Triadic Pharmacology: Molecular Targets, Enzymatic Interactions, and Risk-Benefit Assessment of a Three-Agent Combination for Treatment-Resistant Depression. International Journal of Molecular Sciences, 27(21), 10036. https://doi.org/10.3390/ijms272110036

Vancouver

Fagiolini A, Cuomo A, Corrivetti G, Pinzi M, Carmellini P, Marenna A, et al. Dextromethorphan-Bupropion-Esketamine Triadic Pharmacology: Molecular Targets, Enzymatic Interactions, and Risk-Benefit Assessment of a Three-Agent Combination for Treatment-Resistant Depression. International Journal of Molecular Sciences. 2026;27(21):10036. doi:10.3390/ijms272110036

BibTeX
@article{Fagiolini2026,
  author = {Fagiolini, Andrea and Cuomo, Alessandro and Corrivetti, Giulio and Pinzi, Mario and Carmellini, Pietro and Marenna, Alessandra and Monaco, Francesco and Vignapiano, Annarita and Frigola-Capell, Eva and The Opade Group},
  title = {Dextromethorphan-Bupropion-Esketamine Triadic Pharmacology: Molecular Targets, Enzymatic Interactions, and Risk-Benefit Assessment of a Three-Agent Combination for Treatment-Resistant Depression},
  journal = {International Journal of Molecular Sciences},
  year = {2026},
  volume = {27},
  number = {21},
  pages = {10036},
  doi = {10.3390/ijms272110036}
}
Kostenlos starten →